2 stocks that could be slammed by Donald Trump

Donald Trump’s policies are looking like very bad news for these two UK companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Donald Trump has undoubtedly been a net positive for equities in the US. The new president’s talk of lower taxes, lower regulation and an economic stimulus programme breathed new life into the shares of banks, energy producers and builders alike. But on this side of the Atlantic I have my fears that Trump’s bombastic attacks on certain industries leaves several UK stocks in danger of being hugely negatively affected by his potential policies.

First up is speciality drug producer Shire (LSE: SHP). What worries me about Trump and Shire is that the he’s been quoted in the press as saying things such as “the pricing has been astronomical” and “you folks [drug companies] have done a very great job over the years but we have to get the prices down.

And Trump could definitely do something about bringing down drug prices either through direct legislation or giving government-run medical programmes the ability to negotiate their prices with drug makers. This is a common sense move that has somehow escaped Congress’s attention thus far.

This is a problem for all drug makers but is an extra worry for Shire as the company’s business model is based on developing drugs for rare diseases and then charging very, very high prices for the treatment.

Aside from concerns that its products may fetch lower prices, I’m also worried because Shire has taken on a whopping $23bn in net debt to fund a series of huge acquisitions that have made it a world leader in rare disease treatments. If the company’s ambitious sales and profit targets are met this won’t be a major problem, but should Trump take an axe to pharmaceutical prices, it certainly would be.

Rough seas ahead for global trade?

Also at risk of becoming collateral damage to Trump’s policies is ship broker Clarkson (LSE: CKN). It has already seen profits drop in the past year as a slowdown in demand for oil & gas-related ships and an oversupply of cargo vessels have led to low prices for bulk shipping.

The threat from Trump to Clarkson is if the new president embarks on his much-talked-about plan to impose tariffs on trading partners such as Mexico or, more worryingly, China. Were Trump to slap import taxes on goods from China, the Chinese would undoubtedly retaliate, threatening to send the volume of trade between these important partners plummeting.

This would be a problem for Clarkson because its broking services account for more than 85% of underlying pre-tax profits and would be negatively impacted should volumes and the price of cargo shipping fall.

The upside is that as a broker, Clarkson doesn’t own any ships and is paid a commission per deal arranged, so is somewhat protected from any downturn. Indeed, the company has weathered problems in the offshore oil & gas industry with aplomb and remains solidly profitable and has a cash-heavy balance sheet.

But with shares of the company trading hands at a lofty 25 times forward earnings would-be investors would do well to image the potential threat from Trump’s policies before buying shares.

Are you looking for Trump-resistant shares?

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Where will Rolls-Royce shares go in 2026? Here’s what the experts say!

Rolls-Royce shares delivered a tremendous return for investors in 2025. Analysts expect next year to be positive, but slower.

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Up 40% this year, can the Vodafone share price keep going?

Vodafone shareholders have been rewarded this year with a dividend increase on top of share price growth. Our writer weighs…

Read more »

Buffett at the BRK AGM
Investing Articles

Here’s why I like Tesco shares, but won’t be buying any!

Drawing inspiration from famed investor Warren Buffett's approach, our writer explains why Tesco shares aren't on his shopping list.

Read more »

Investing For Beginners

If the HSBC share price can clear these hurdles, it could fly in 2026

After a fantastic year, Jon Smith points out some of the potential road bumps for the HSBC share price, including…

Read more »

Investing Articles

I’m thrilled I bought Rolls-Royce shares in 2023. Will I buy more in 2026?

Rolls-Royce has become a superior company, with rising profits, buybacks, and shares now paying a dividend. So is the FTSE…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With Warren Buffett about to step down, what can investors learn?

Legendary investor Warren Buffett is about to hand over the reins of Berkshire Hathaway after decades in charge. How might…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

I asked ChatGPT for the perfect passive income ISA and it said…

Which 10 passive income stocks did the world's most popular artificial intelligence chatbot pick for a Stocks and Shares ISA?

Read more »

Tŵr Mawr lighthouse (meaning "great tower" in Welsh), on Ynys Llanddwyn on Anglesey, Wales, marks the western entrance to the Menai Strait.
Investing Articles

How I generated a 66.6% return in my SIPP in 2025 (and my strategy for 2026!)

By focusing on undervalued, high-potential stocks, this writer achieved market-beating SIPP returns in 2025 – here’s how he aims to…

Read more »